Archive: March 16, 2022

FDA approves IND application for peanut allergen vaccine. Phase I study in peanut allergy patients to begin May 2022

Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut Paves the way for start of VLP Peanut vaccine candidate’s Phase I PROTECT trial in H1 2022 Topline data from first-in-human trial expected in H1 2023 Analysis of data from earlier ex-vivo biomarker study, VLP001, demonstrates beneficial mode of …

Read More